News & Events
Crinetics Pharmaceuticals to Participate in the Jefferies Global Healthcare Conference 2025
will participate in the Jefferies Global Healthcare Conference, taking place June 3-5, 2025 in New York, NY.
READ MORECrinetics to Present New Research on Paltusotine, Atumelnant and Unmet Needs in Acromegaly Treatment at the American Association of Clinical Endocrinology Annual Meeting 2025
New Analysis Shows Treatment with Investigational Paltusotine Resulted in Rapid and Durable IGF-1 Control in Surgically Naïve Acromegaly PatientsAdditional Research Includes Acromegaly Symptom Burden and Standard-of-Care Discontinuation Rates SAN DIEGO – May 15, 2025 – Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX), today announced it will present two abstracts at the American Association of Clinical Endocrinology (AACE) Annual Meeting 2025, taking place May 15–17 in Orlando, FL. One presentation is a post-hoc analysis showing investigational candidate paltusotine provided rapid and durable treatment effects and was well tolerated in surgically naïve patients with acromegaly.
READ MORECrinetics Pharmaceuticals Announces May 2025 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Crinetics granted non-qualified stock option awards to purchase an aggregate of 152,475 shares of its common stock and an aggregate of 101,800 restricted stock unit awards to 35 new non-executive employees.
READ MORECrinetics Pharmaceuticals Reports First Quarter 2025 Financial Results and Provides Business Update
Crinetics Pharmaceuticals reports first quarter 2025 financial results and provided a business update on May 8, 2025 at 4:30PM ET.
READ MORECrinetics Pharmaceuticals Announces April 2025 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Crinetics granted non-qualified stock option awards to purchase an aggregate of 124,950 shares of its common stock and an aggregate of 84,725 restricted stock unit awards to 26 new non-executive employees.
READ MORECrinetics Pharmaceuticals Announces European Medicines Agency (EMA) Validation of Marketing Authorization Application (MAA) and Orphan Drug Designation (ODD) for Paltusotine in Acromegaly
Crinetics announces European Medicines Agency Validation of Marketing Authorization Application and Orphan Drug Designation for paltusotine in acromegaly.
READ MORECrinetics Pharmaceuticals Announces March 2025 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Crinetics granted non-qualified stock option awards to purchase an aggregate of 95,675 shares of its common stock to fifteen new non-executive employees and 80,000 to one new executive employee.
READ MORECrinetics Pharmaceuticals Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update
Crinetics Pharmaceuticals Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update.
READ MORETransforming Endocrine Disease Treatment
Be the first to know about the advances we're making in endocrine-rooted care.
Email Signup
Please click CONTINUE below to learn more about a new treatment option. This website contains information about a prescription medicine.
